What do we know about the renin angiotensin system and inflammatory bowel disease?
INTRODUCTION: The renin-angiotensin system (RAS) is an important homeostatic pathway, with emerging evidence for the impact of its components on inflammation and fibrosis in gastrointestinal tissues. This review aims to review current knowledge of the physiological mechanism of RAS in inflammatory bowel disease (IBD), and potential therapeutic implications.
AREAS COVERED: An extensive online literature review including Pubmed, Medline, and Google Scholar was undertaken. Discussion on the components of the RAS, localization, and physiological functions in the gastrointestinal tract, preclinical, and clinical data in IBD, and the relation with SARS-Cov-2 are covered in this review.
EXPERT OPINION: RAS inhibition may have a role as anti-fibrotic adjunct therapy. Targeting the local gastrointestinal RAS with novel modes of delivery may be a target for future therapeutics for IBD, given the widespread availability and safety of current options as utilized in other diseases. Further insight into the mechanism and downstream effects of gastrointestinal ACE2 may lead to a better understanding of the pathogenesis of IBD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Expert opinion on therapeutic targets - 26(2022), 10 vom: 21. Okt., Seite 897-909 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lo, Sheng Wei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiotensin converting enzyme 2 |
|---|
| Anmerkungen: |
Date Completed 26.01.2023 Date Revised 02.02.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14728222.2022.2157261 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349967288 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349967288 | ||
| 003 | DE-627 | ||
| 005 | 20231226043902.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14728222.2022.2157261 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1166.xml |
| 035 | |a (DE-627)NLM349967288 | ||
| 035 | |a (NLM)36484415 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lo, Sheng Wei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a What do we know about the renin angiotensin system and inflammatory bowel disease? |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2023 | ||
| 500 | |a Date Revised 02.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: The renin-angiotensin system (RAS) is an important homeostatic pathway, with emerging evidence for the impact of its components on inflammation and fibrosis in gastrointestinal tissues. This review aims to review current knowledge of the physiological mechanism of RAS in inflammatory bowel disease (IBD), and potential therapeutic implications | ||
| 520 | |a AREAS COVERED: An extensive online literature review including Pubmed, Medline, and Google Scholar was undertaken. Discussion on the components of the RAS, localization, and physiological functions in the gastrointestinal tract, preclinical, and clinical data in IBD, and the relation with SARS-Cov-2 are covered in this review | ||
| 520 | |a EXPERT OPINION: RAS inhibition may have a role as anti-fibrotic adjunct therapy. Targeting the local gastrointestinal RAS with novel modes of delivery may be a target for future therapeutics for IBD, given the widespread availability and safety of current options as utilized in other diseases. Further insight into the mechanism and downstream effects of gastrointestinal ACE2 may lead to a better understanding of the pathogenesis of IBD | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Angiotensin converting enzyme 2 | |
| 650 | 4 | |a angiotensin converting enzyme inhibitor | |
| 650 | 4 | |a angiotensin receptor blocker | |
| 650 | 4 | |a gastrointestinal tract | |
| 650 | 4 | |a inflammatory bowel disease | |
| 650 | 4 | |a renin angiotensin system | |
| 700 | 1 | |a Segal, Jonathan P |e verfasserin |4 aut | |
| 700 | 1 | |a Lubel, John S |e verfasserin |4 aut | |
| 700 | 1 | |a Garg, Mayur |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on therapeutic targets |d 2001 |g 26(2022), 10 vom: 21. Okt., Seite 897-909 |w (DE-627)NLM117849634 |x 1744-7631 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2022 |g number:10 |g day:21 |g month:10 |g pages:897-909 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14728222.2022.2157261 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2022 |e 10 |b 21 |c 10 |h 897-909 | ||